Mulakan
AlenCiken

Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838

Immunic, Inc. (NASDAQ:IMUX)  
AlenCiken  
NASDAQ:IMUX   Immunic, Inc.
Fundamental Analysis Trend Analysis Chart Patterns
5
0
fundamental trendanalysis chartpattern
Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

Study Meets Primary and Key Secondary Endpoints with High Statistical Significance

Statistically Significant Reduction of 62% and 70%

Data Supports Previously Observed Favorable Safety Profile of IMU-838 in Relapsing-Remitting Multiple Sclerosis Patient Population -

- Company Also Reports Second Quarter 2020 Financial Results With $48.6 Million in Cash and Cash Equivalents -

finance.yahoo.c...-190000055.html?guce_refer...

Penafian

Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.